Q/C Technologies, Inc.
QCLS- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001321834
No open-market purchases or sales by Q/C Technologies, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $2.87M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Q/C Technologies, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Q/C Technologies, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Voss Chelsea Sierra | Director | 61,555Indirect | May 14, 2026 | 3 |
| Silverman Joshua | Executive Chairman | 262,191 | Apr 15, 2026 | 3 |
| White Billy Joe | Director | 25,024 | Apr 15, 2026 | 3 |
| Bernstein Bruce | Director | 25,000 | Apr 15, 2026 | 2 |
| Glass Mitchell | Chief Medical Officer | 12,500 | Apr 15, 2026 | 3 |
| Friscia Stephen | Director | 25,000 | Apr 15, 2026 | 3 |
| PharmaCyte Biotech, Inc. | 10% Owner | – | Nov 18, 2025 | 1 |
| Rauch Gary M | Other: Vice President of Finance | 12,500 | Nov 14, 2025 | 2 |
| Rhodes Ian | Interim CFO | – | Apr 18, 2025 | 0 |
| Rivard Paul | Chief Legal Officer | 400,000 | Aug 24, 2023 | 0 |
| Chapman Christopher C JR | President, Chief Med. Officer | – | Jun 9, 2023 | 0 |
| Eagle Craig | Director | – | Jun 9, 2023 | 0 |
| Schreiber Christopher C | Director | – | Jun 9, 2023 | 0 |
| Uzonwanne Jude | Director | – | Jun 9, 2023 | 0 |
| Kaplin Adam | Chief Scientific Officer | – | Jun 9, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 14, 2026 (view filing) | Mar 30 | 45 daysLate | Voss Chelsea SierraDirector | PPurchase | +1.75K | $3.15 | +$5.52K | +2.9%61.6K after | |
| Nov 18, 2025 (view filing) | Sep 4-Nov 14 | 75 daysLate | PharmaCyte Biotech, Inc.10% Owner | PPurchaseCommon stock, par value $0.001 per share | +1.78M | – | – | –889.9K after | Derivative2 lots |
| Aug 24, 2023 (view filing) | Aug 24 | Same day | Rivard PaulChief Legal Officer | PPurchase | +150.0K | $1.11 | +$166.5K | +60.0%400.0K after | |
| Aug 18, 2023 (view filing) | Aug 17 | 1 day | Rivard PaulChief Legal Officer | PPurchase | +25.0K | $1.12 | +$28.0K | +11.1%250.0K after | |
| Dec 8, 2022 (view filing) | Dec 8 | Same day | Rivard PaulEVP of Operations, GC | PPurchase | +10.0K | $1.53 | +$15.3K | +4.7%225.0K after | |
| Nov 29, 2021 (view filing) | Nov 24-26 | 5 days | Silverman JoshuaDirector | PPurchase | +15.0K | $6.89 | +$103.3K | +20.3%88.8K after | 3 lots |
| Nov 24, 2021 (view filing) | Nov 23 | 1 day | Rivard PaulEVP of Operations, GC | PPurchase | +15.0K | $6.03 | +$90.5K | +7.5%215.0K after |